BTIG analyst Marie Thibault said the price was “in line with our prior $100 per month assumption.” Dexcom’s device is intended for people with Type 2 diabetes who don’t take insulin ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing ...

Today, Benzinga 's options scanner spotted 8 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...

In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of $115.00 ... Its products include DexCom G4 PLATINUM ...

Shares of DexCom Inc. DXCM slid 2.07% to $70.43 Friday, on what proved to be an all-around mixed trading session for the ...

Dexcom (Nasdaq:DXCM) today announced a collaboration to establish National Glucose Awareness Week from Sept. 23-29, 2024.

Lastly, DexCom's shares look expensive. As of this writing, the healthcare industry's average forward price-to-earnings ratio is 19.5. How much will that matter in more than 10 years, though?

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

After getting the green light from the FDA back in March, Dexcom today launched its first ... The over-the-counter component and the price point were designed specifically to allow more people ...

DexCom Inc (DXCM) stock saw a decline, ending the day at $68.94 which represents a decrease of $-1.15 or -1.64% from the prior close of $70.09. The stock opened at $69.99 and touched a low of $68.59 ...